Angioplasty Balloons Market Size, Share, Opportunities, And Trends By Type (Normal Balloons, Drug Eluting Balloons, Cutting Balloons, Scoring Balloons), By Application (Peripheral, Coronary), By End-Use (ASCs, Hospitals, Cath Labs), And By Geography - Forecasts From 2023 To 2028

The angioplasty balloons market is anticipated to show steady growth during the forecast period.

Angioplasty balloons are medical devices used in a procedure called angioplasty, where they help open narrowed or blocked blood vessels. These balloons are typically inserted into the affected artery or vessel through a catheter, which is a thin, flexible tube that is inflated to widen the area and improve blood flow.

The increasing prevalence of cardiovascular diseases, favourable regulatory environment coupled with the growing adoption of minimally invasive procedures have emerged as the significant driving force behind the substantial growth of the angioplasty balloons industry.

Market Drivers:

• The increasing prevalence of cardiovascular diseases bolsters the angioplasty balloons market growth.

Angioplasty balloons play a pivotal role in the treatment of cardiovascular diseases, specifically in procedures aimed at opening narrowed or blocked blood vessels. These balloons are used in angioplasty, where they are inserted into the affected artery and inflated to widen the vessel, restoring blood flow to the heart or other parts of the body. As these conditions become more widespread globally, the need for interventional procedures like angioplasty is also on the rise. For instance, according to the World Health Organisation (WHO), cardiovascular diseases (CVDs) stand as the leading global cause of mortality, claiming approximately 17.9 million lives annually, underscoring the increasing prevalence of cardiovascular diseases and the critical need for effective interventions such as angioplasty for the treatment of these diseases.

• Favourable regulatory environment drives angioplasty balloons market growth.

Regulatory bodies worldwide are recognizing the benefits of angioplasty balloons and have streamlined approval processes for these devices. This supportive regulatory environment facilitates market growth and encourages innovation in the angioplasty balloons industry. For instance, in February 2023, Concept Medical received Investigational Device Exemption (IDE) approval for their Magic Touch Sirolimus Coated Balloon, intended to treat Below the Knee (BTK) Arterial Disease. Moreover, streamlined approval processes enable faster market access for newer and improved angioplasty balloons. This expedites the availability of cutting-edge technologies to healthcare providers, allowing them to offer state-of-the-art treatments to patients promptly.

• The adoption of minimally invasive procedures drives the angioplasty balloons market expansion.

Angioplasty balloons are a critical component in angioplasty, a minimally invasive technique used to widen narrowed or blocked blood vessels. During the procedure, the balloon is inserted into the affected artery and inflated to widen the vessel, restoring proper blood flow without the need for extensive surgical incisions. The shift toward minimally invasive procedures is fueled by various factors such as advancements in medical technology, patient preference for less invasive treatments, and the desire to reduce hospital stays and recovery periods. As healthcare trends increasingly favor less invasive treatment options, procedures like angioplasty gain prominence driving the growth of angioplasty balloons.

North America is expected to dominate the market.

North America is projected to account for a major share of the angioplasty balloons market owing to the region’s strong healthcare infrastructure and high prevalence of cardiovascular diseases, particularly in countries like Canada and the United States which stimulates the angioplasty balloons demand. For instance, according to the Centre for Disease Control and Prevention, in the United States, one person dies every 33 seconds from cardiovascular disease. As per the same source, in 2022, approximately 695,000 individuals in the United States passed away due to heart disease, representing 1 out of every 5 fatalities, underscoring the substantial burden of cardiovascular diseases and the need for effective treatment options like angioplasty balloons.

Market Challenges:

• Competition from alternatives will restrain the angioplasty balloons market growth.

The growth of the angioplasty balloons industry may be restrained by the competition from alternative technologies available for treating cardiovascular diseases, such as drug-eluting stents and transcatheter aortic valve replacement (TAVR). These alternatives often compete directly with angioplasty balloons by offering comparable or enhanced efficacy, safety, and patient outcomes. Drug-eluting stents, for example, combine mechanical vessel widening with drug delivery, addressing both immediate vessel dilation and reducing the risk of restenosis. These alternative solutions pose a challenge to the market's expansion and may require the angioplasty balloons industry to continue the advancements and innovations in balloon technology to remain competitive in a changing landscape.

Market Developments

• March 2022: The FDA approved the Philips Image Guided Therapy Corporation's Stellarex 0.035” OTW Drug-coated Angioplasty Balloon. This device, known as the Stellarex 035 DCB, utilizes a drug-coated balloon to treat narrowed or blocked arteries in the thigh and knee caused by peripheral artery disease (PAD). The balloon's outer surface is coated with the drug paclitaxel, potentially reducing the likelihood of arteries narrowing again (restenosis).
• July 2021:  MedAlliance launched ORIGIN SC and ORIGIN NC, two high-performance balloons designed for vessel preparation. These balloons complement SELUTION SLR™, the company's innovative sirolimus-eluting balloon. ORIGIN SC boasts a low crossing profile, ideal for complex lesions, while ORIGIN NC offers high-pressure tolerance and controlled compliance for challenging cases with an optimal crossing profile.

Company Products

• Emerge™: The Emerge Catheter blends the Boston Scientific balloon technologies, delivering exceptional deliverability with an ultra-low profile. This balloon catheter navigates and crosses challenging lesions effortlessly. Offering a high burst pressure rating of 18 ATM (1824 kPa) for flexibility in sizing and two shaft design options for complex lesions, its profile enables simultaneous use of two Monorail™ catheters in a 6 F guide catheter or two Over-the-Wire catheters in an 8 F guide catheter.
• Precision Angioplasty: Infinity Angioplasty Balloon™ Company innovated PTA balloon catheters for minimally invasive infra-inguinal PAD treatment. Utilizing proprietary technology, their INFINITY Precision Angioplasty® balloons adapt to lesions ranging from 40mm to 250mm IN VIVO. The interventionalist can precisely control their length, covering over 95% of PAD size requirements with accuracy.
• EverCross PTA Balloon Catheter: Medtronic's EverCross 0.035” OTW PTA dilatation catheter aims to widen stenoses in various arteries like iliac, femoral, popliteal, and others, including arteriovenous dialysis fistulae. It's also suitable for post-dilatation of stents in peripheral vasculature. The catheter's distal flexibility aids smooth navigation through intricate anatomy, while its strong shaft design ensures resistance to buckling, allowing for reliable push ability.

Segmentation

• By Type
  • Normal Balloons
  • Drug Eluting Balloons
  • Cutting Balloons
  • Scoring Balloons
• By Application
  • Peripheral
  • Coronary
• By End-Use
  • ASCs
  • Hospitals
  • Cath Labs
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Indonesia
    • Thailand